2012年 · 第32卷第01期

colorectal cancer (CRC) is a common malignant tumor in China. In western developed countries, the incidence of CRC ranks 2nd to 3rd among malignant tumors. With the continuous improvement of Chinese people's living standard and the change of dietary habits, the incidence of CRC in China is also increasing year by year, and has jumped to the third ~ fifth place, especially in big cities. colorectal adenoma (CRA) is the most important precancerous disease of CRC^[1,2,3]。 It is generally believed that colorectal tumors mainly include CRC and CRA.

GUTIn April 2011, the Asia-Pacific expert consensus on non-varicose upper gastrointestinal bleeding (hereinafter referred to as the Asia-Pacific consensus) was published online. According to the actual situation in the Asia-Pacific region, this consensus opinion elaborates on the 12 most common clinical key problems of nonvariceal upper gastrointestinal bleeding (NVUGIB), and puts forward guidance for its treatment. In order to better enable the majority of clinicians in China to understand the above consensus opinions according to the specific situation of China, several domestic gastroenterology experts interpreted several main components of the Asia-Pacific consensus respectively.

nonvariceal upper gastrointestinal bleeding (NVUGIB) is one of the common acute and severe diseases in gastroenterology. 2010 NVUGIB International Consensus Opinion (ICON-UGIB)^[1]It is clearly indicated how risk assessment, resuscitation and preendoscopic management are performed in such patients, and in 2011GUTThe journal published the consensus opinion of experts on non-varicose upper gastrointestinal bleeding in the Asia-Pacific region online (hereinafter referred to as the Asia-Pacific consensus), and formulated the treatment guidelines for NVUGIB more in line with the Asian population according to the actual situation in Asia (such as economic level, drug metabolism characteristics, etc.). Among them, risk assessment, resuscitation and preendoscopic management play an important role in the early management and prognosis of NVUGIB patients. The Asia-Pacific consensus of this part of the guidelines is now elaborated.